Dr. John M Wallmark
Claim this profileGSK Investigational Site
Studies Lung Cancer
Studies Tumors
3 reported clinical trials
3 drugs studied
Area of expertise
1Lung Cancer
Stage IV
Stage III
EGFR positive
2Tumors
Stage IV
Stage III
Affiliated Hospitals
Clinical Trials John M Wallmark is currently running
TSR-022
for Advanced Cancer
This trial is testing TSR-022, a new medicine that helps the immune system fight cancer by blocking a protein called TIM-3. TIM-3 has gained prominence as a potential candidate for cancer immunotherapy, where it has been shown that blocking TIM-3 with other treatments enhances the body's ability to fight tumors and suppress their growth. It targets patients with tumors, especially those who may not respond to standard treatments. The goal is to see if this medicine can help the immune system better attack cancer cells.
Recruiting1 award Phase 1
Reqorsa + Osimertinib
for Advanced Lung Cancer
The purpose of this randomized study is to determine the safety and efficacy of quaratusugene ozeplasmid (Reqorsa) added to osimertinib in NSCLC patients with activating EGFR mutations who have progressed while on treatment with osimertinib. Quaratusugene ozeplasmid consists of non-viral lipid nanoparticles that encapsulate a DNA plasmid with the TUSC2 tumor suppressor gene and is the first systemic gene therapy for cancer. The study is comprised of a Phase 1 dose escalation portion and two Phase 2 portions evaluating safety and efficacy. Enrollment in the Phase 1 dose escalation portion is complete and the recommended Phase 2 dose (RP2D) was determined. Phase 2a has initiated and enrolled patients are treated with quaratusugene ozeplasmid at the RP2D in combination with osimertinib. In Phase 2b, patients will be randomized to receive either quaratusugene ozeplasmid plus osimertinib or platinum-based chemotherapy.
Recruiting1 award Phase 1 & 2
More about John M Wallmark
Clinical Trial Related9 years of experience running clinical trials · Led 3 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments John M Wallmark has experience with
- TSR-022
- Osimertinib
- Quaratusugene Ozeplasmid
Breakdown of trials John M Wallmark has run
Non-Small Cell Lung Cancer
Cancer
Melanoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does John M Wallmark specialize in?
John M Wallmark focuses on Lung Cancer and Tumors. In particular, much of their work with Lung Cancer has involved Stage IV patients, or patients who are Stage III.
Is John M Wallmark currently recruiting for clinical trials?
Yes, John M Wallmark is currently recruiting for 2 clinical trials in Rockville Maryland. If you're interested in participating, you should apply.
Are there any treatments that John M Wallmark has studied deeply?
Yes, John M Wallmark has studied treatments such as TSR-022, Osimertinib, Quaratusugene Ozeplasmid.
What is the best way to schedule an appointment with John M Wallmark?
Apply for one of the trials that John M Wallmark is conducting.
What is the office address of John M Wallmark?
The office of John M Wallmark is located at: GSK Investigational Site, Rockville, Maryland 20850 United States. This is the address for their practice at the GSK Investigational Site.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.